Skip to main content

Table 2 Summary of interviews with patients/caretakers

From: Feasibility and acceptability of injectable artesunate for the treatment of severe malaria in the Democratic Republic of Congo

Question/parameter

Frequency

Percentage [95 % CI]

Time to observe effects of injectable artesunate compared to quinine (N = 134)?

 Less time

125

93.3 [87.6, 96.9]

 Same time

8

6 [2.6, 11.4]

 More time

1

0.7 [0.0, 4.1]

Have you noticed any adverse event that you think could be related to artesunate (N = 134)?

 Yes

46

34.3 [26.4, 43.0]

 No

88

65.7 [57.0, 73.7]

If you noticed adverse events, would you say that: (N = 46)

 They are less than those observed with quinine

32

69.6 [54.3, 82.3]

 They are the same than those observed with quinine

7

15.2 [6.3, 28.9]

 They are more than those observed with quinine

1

2.1 [0.0, 11.5]

 Don’t know

6

13.1 [4.9, 26.3]

If you had to make the choice in the future between quinine and artesunate, which one would you choose (N = 121)?

 Quinine

4

3.3 [0.9, 8.2]

 Artesunate

117

96.7 [91.8, 99.1]

What is your level of satisfaction towards injectable artesunate (N = 134)?

 Dissatisfied

6

4.5 [1.7, 9.5]

 Satisfied

66

49.2 [40.5, 58.0]

 Very satisfied

62

46.3 [37.6, 55.1]

Most important reasons for choosing injectable artesunate instead of injectable quinine (N = 117)

 Rapid action

55

47.0 [37.7, 56.5]

 No side effects

38

32.5 [24.1, 41.8]

 Short treatment course

24

20.5 [13.6, 28.9]

 Less side effects

14

12.0 [6.7, 19.3]

 Rapid way of administration

13

11.1 [6.1, 18.3]

 Short hospital stay

7

6.0 [2.4, 11.9]

 More effective

5

4.2 [1.4, 9.7]